Back
Regeneron Pharmaceuticals, Inc. 10K Form
Buy
60
REGN
Regeneron Pharmaceuticals, Inc.
Last Price:
$790.34
Seasonality Move:
0.58%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | REGN/Regeneron Pharmaceuticals, Inc. Quarterly |
| 2023-11-02 | 10Q | REGN/Regeneron Pharmaceuticals, Inc. Quarterly |
| 2023-08-03 | 10Q | REGN/Regeneron Pharmaceuticals, Inc. Quarterly |
| 2023-05-04 | 10Q | REGN/Regeneron Pharmaceuticals, Inc. Quarterly |
| 2022-11-03 | 10Q | REGN/Regeneron Pharmaceuticals, Inc. Quarterly |
| 2022-08-03 | 10Q | REGN/Regeneron Pharmaceuticals, Inc. Quarterly |
Receive REGN News And Ratings
See the #1 stock for the next 7 days that we like better than REGN
REGN Financial Statistics
Sales & Book Value
| Annual Sales: | $14.3B |
|---|---|
| Cash Flow: | $880M |
| Price / Cash Flow: | 23.17 |
| Annual Sales: | $295.71 |
| Price / Book: | 2.72 |
Profitability
| EPS (TTM): | 41.56260 |
|---|---|
| Net Income (TTM): | $4.5B |
| Gross Margin: | $11.7B |
| Return on Equity: | 14.93% |
| Return on Assets: | 11.59% |
Regeneron Pharmaceuticals, Inc. Earnings Forecast
Key Regeneron Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 36 years for REGN is 81.56%.
-
The Selling, General & Administrative Expenses for REGN have been equal to 18.82% of Gross Profit Margin.
-
The Research & Development expenses have been 37.00% of Revenue.
-
The Interest Expense is 0.97% of Operating Income.
-
The Net Earning history of REGN is 31.41% of Total Revenues.
-
Per Share Earnings over the last 36 years have been positive in 20 years.
Regeneron Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | REGN |
| CUSIP: | 75886F |
| Website: | regeneron.com |
Debt
| Debt-to-Equity Ratio: | 0.1 |
|---|---|
| Current Ratio: | 4.13 |
| Quick Ratio: | 3.29 |
Price-to-Earnings
| Trailing P/E Ratio: | 19.36 |
|---|---|
| Forward P/E Ratio: | 15.28 |
REGN Technical Analysis vs Fundamental Analysis
Buy
60
Regeneron Pharmaceuticals, Inc. (REGN)
is a Buy
Is Regeneron Pharmaceuticals, Inc. a Buy or a Sell?
-
Regeneron Pharmaceuticals, Inc. stock is rated a BuyThe current Regeneron Pharmaceuticals, Inc. [REGN] share price is $803.17. The Score for REGN is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.